BTIG Initiates Coverage On ORIC Pharmaceuticals with Buy Rating, Announces Price Target of $26

BTIG analyst Jeet Mukherjee initiates coverage on ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy rating and announces Price Target of $26.